Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
暂无分享,去创建一个
A. Pileri | C. Voena | M. Ladetto | M. Tresoldi | C. Bordignon | F. Ciceri | A. Rambaldi | P. Corradini | A. Gianni | M. Bregni | C. Tarella | F. Zallio | F. Benedetti | A. Olivieri | M. Falda | A. Dodero | M. Lucesole | M. Sajeva
[1] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[2] P. Thall,et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.
[3] A. Romanelli,et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Morgan,et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. , 2000, Blood.
[5] F. Frassoni,et al. Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age , 2000, British journal of haematology.
[6] S. Nantel,et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia , 2000, Bone Marrow Transplantation.
[7] E. Macintyre,et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.
[8] Cahn,et al. Allogeneic bone marrow transplantation in aggressive non‐Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database , 1999 .
[9] A. Pileri,et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions , 1999, Leukemia.
[10] M. Florek,et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection , 1999, Bone Marrow Transplantation.
[11] J. Raemaekers,et al. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) , 1998, The Lancet.
[12] J. Armitage,et al. Allogeneic bone marrow transplantation for low-grade lymphoma. , 1998, Blood.
[13] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[15] R. Setroikromo,et al. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice , 1998, Bone Marrow Transplantation.
[16] J. Cornelissen,et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.
[17] N. Callander,et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation , 1997, Bone Marrow Transplantation.
[18] J. Gribben,et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors , 1997, Leukemia.
[19] E. Estey,et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.
[20] A. Pileri,et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. , 1997, Blood.
[21] R. Storb,et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.
[22] J. Gribben,et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. , 1996, Blood.
[23] J. Armitage,et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Mackinnon,et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.
[25] F. Berger,et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. , 1994, Blood.
[26] E. Dmitrovsky,et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. , 1993, Blood.
[27] A A Rimm,et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. , 1993, JAMA.
[28] J. Gribben,et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.
[29] H. Deeg,et al. Bone marrow transplantation in patients aged 45 years and older. , 1986, Blood.
[30] F. Frassoni,et al. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. , 2001, Haematologica.
[31] J. Román,et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. , 2000, Blood.
[32] A. Palumbo,et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Strober,et al. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.
[34] H. Schmetzer,et al. Minimal residual disease in acute leukemia. , 1991, European journal of cancer.
[35] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.